[ad_1]
Germany has pressured the European Union authorities to speed up the Covid-19 vaccine approval process from Pfizer-BioNTech, which are already beginning to use several countries, including Great Britain, the United States and Canada. Chancellor Angela Merkel and the German Health Ministry have called on EMA and EU leaders for the drug to be approved. before December 23 (and not on December 29 as planned). To report it, in the morning, it was the newspaper image, citing sources close to the German government. News that confirms the signs of impatience already expressed on Sunday by the German Minister of Health, Jens spahn. All data from BioNTech (German biotechnology company, ed) are available, UK and US have already given their approval. The data review and EMA approval should take place as soon as possible, he said, clarifying how confidence in the European Union’s ability to act depends on it. Our goal – Spahn emphasized – was to be approved before Christmas so we can start vaccinating this year. We are optimistic that the vaccine can be licensed in Europe on December 23, he concluded.
Gass: What need is there to wait until December 29?
Statements also supported by the President of the German Hospital Society, Gerald Gass: I wonder if we really have to wait until December 29, he attacked, launching the proposal to establish a European emergency license. In Germany, as in other EU member states, the authority of the European Medicines Agency is still awaited.
Ema anticipates the extraordinary meeting for December 21
And the European Medicines Agency (Ema) has announced that will present the vaccine authorization decision from December 29 to 21 against the coronavirus, specifying that the Committee for Medicinal Products for Human Use (CHMP) and its experts have worked intensively in recent weeks to evaluate the data presented by BioNTech and Pfizer. A special meeting is scheduled for Dec. 21 to reach a conclusion if possible, a note reads. Just a little earlier However, an Ema spokesperson had underlined: The approval date for the Pfizer-BionTech vaccine remains December 29.. If there is any change, we will announce it. A decision also welcomed by the President of the European Commission, Ursula von der Leyen, who wrote on Twitter: Every day counts. We are working at full speed to authorize vaccines for Covid 19. I welcome the news from the EMA that anticipates the meeting to discuss the Pfizer-BioNTech vaccine before Christmas. The first Europeans are likely to be vaccinated before the end of 2020.
Every day counts: we work at full speed to authorize # COVID-19 vaccines that are safe and effective.
I welcome @EMA_News moving forward their meeting to discuss the vaccine @ pfizer / BioNTech, before Christmas.
The first Europeans are likely to be vaccinated before the end of 2020!
– Ursula von der Leyen (@vonderleyen) December 15, 2020
Hope: We look forward to an advance of the times.
The Berlin appeals have also found a favorable side in Italy, where the Minister of Health Roberto Speranza it has always claimed the role of the country’s leader in organizing the vaccine reserve, already before last summer, on a continental level. My hope – made clear – that the EMA, in compliance with all safety procedures, can approve the Pfizer BioNTech vaccine earlier than expected and that vaccinations can start as soon as possible also in the countries of the Union. European. Meanwhile, the Minister for Regional Affairs, Francesco Boccia, announces that tomorrow (16 December ed.) with Minister Speranza, Commissioner Arcuri and the head of the Department of Civil Protection Borrelli we will hold the final meeting to launch the vaccine plan. Arcuri is ready to give the green light to the vaccine distribution plan as soon as the EU is okay. The regions have done an excellent job, he stressed.
Fda optimistic about Moderna: Positive evaluation, towards Friday ok
The good news also comes from the vaccine produced by Moderna. The Food and Drug Administration (FDA), the US drug agency, issued a positive evaluation on the vaccine from the American Modern laboratory, paving the way for the approval of a second vaccine after that of Pfizer / BioNTech. The FDA says it is optimistic about the vaccine and says it does not show specific safety concerns that would prevent it from issuing an emergency use permit. The agency also confirmed that the treatment was 94.1% effective. Encouraging data suggesting authorization will be granted on Friday, sources at the US drug regulator. New York Times.
The vaccine plan in Italy
December 15, 2020 (modified on December 15, 2020 | 15:34)
© REPRODUCTION RESERVED
[ad_2]
